A study comparing the efficacy of antimicrobial agents versus enzyme (P-gp) inducers in the treatment of 2,4,6 trinitrobenzenesulfonic acid-induced colitis in rats

Journal of Physiology and Pharmacology

Volumn 64, Issue 4, 2013, Pages 439-451

  Toklu, Hale Zerrin ^a   Kabasakal, L ^a   Imeryuz, N ^b   Kan, B ^c   Celikel, C ^b   Cetinel, S ^b   Orun, O ^b   Yuksel, M ^a   Dulger, Gul Ayanoglu ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Ciprofloxacine; Colitis; Nuclear factor B; P glycoprotein; Rifampicin; Spironolacton

Indexed keywords

CIPROFLOXACIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; RIFAMPICIN; SPIRONOLACTONE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ENTERITIS; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; RAT MODEL; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLITIS; COLON; GLUTATHIONE; ILEUM; MALE; MALONDIALDEHYDE; NF-KAPPA B; P-GLYCOPROTEIN; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, STEROID; RIFAMPIN; SPIRONOLACTONE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884928684     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003; 52: 759-766.
2. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-5744.
3. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of Pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40.
4. Iizasa H, Genda N, Kitano T, et al. Altered expression and function of P-glycoprotein in dextran sodium sulfateinduced colitis in mice. J Pharm Sci 2003; 92: 569-676.
5. Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 2005; 69: 1745-1754.
6. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
7. Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003; 17: 47-61.
8. Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-Xreceptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010; 80: 1700-1707.
9. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1114-G1122.
10. Zhou C, Tabb MM, Nelson EL, et al. Mutual expression between steroid and xenobiotic receptor and NF-kB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006; 116: 2280-2289.
11. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687-702.
12. Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335: 32-41.
13. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633.
14. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol 2011; 106: 661-673.
15. Lahat G, Halperin D, Barazovsky E, et al. Immunomodulatory effects of ciprofloxacine in TNBS-induced colitis in mice. Inflamm Bowel Dis 2007; 13: 557-565.
16. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on p-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 2004; 32: 1008-1014.
17. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: undelying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrobial 2006; 5: 3-13.
18. Schuetz EG, Brimer C, Schuetz JD. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP 3A23 hormone response element. Mol Pharmacol 1998; 54: 1113-1117.
19. Gnahem CI, Gomez PC, Arana MC, et al. Induction of rat intestinal p-glycoprotein by spironolactone and its effect on absoption of orally administered digoxin. J Pharmacol Exp Ther 2006; 318: 1146-1152.
20. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
21. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29-36.
22. Amedo CK, Adjei AA, Harrison EK, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumor necrosis factor alpha production in trinitrobenzene sulfonic acid induced colitis. Gut 1997; 41: 487-493.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
24. Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-311.
25. Beutler E. Glutathion in Red Blood Cell Metabolism. A Manual of Biochemical Methods. New York, Grune & Stratton, 1963; pp. 112-114.
26. Hillegas LM, Griswold DE, Brickson B, Albrightson WC. Assesment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990; 24: 285-295.
27. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 92: 2546-2551.
28. Li JH, Yu JP, Yu H-G, Xu X-M, Yu L-L, Liu S-Q. Expression and significance of nuclear factor kB p65 in colon tissues of rats with TNBS-induced colitis. World J Gastroenterol 2005; 11: 1759-1763.
29. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-14587.
30. Linskens RK, Huijdens XW, Savelkoul PH, Vanderbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insight in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001; 234: 29-40.
31. Gionchetti P, Rizzello F, Venturi A, et al. Review-Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci 1999; 3: 27-30.
32. Zwolinska-Wcislo M, Krzysiek-Maczka G, Ptak-Belowska A, et al. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. J Physiol Pharmacol 2011; 62: 357-368.
33. Ghasemmi-Niri SF, Abdolghaffari AH, Fallah-Benakohal S, et al. On the benefit of whey-cultured Lactobacillus casei in murine colitis. J Physiol Pharmacol 2011; 62: 341-346.
34. Saksena S, Goyal S, Raheja G, et al. Upregulation of Pglycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1115-G1123.
35. Blokzijl H, Vander Borght S, Bok LI, et al. Decreased Pglycoprotein (P-gp/MDRI) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 2007; 13: 710-720.
36. Ma X, Shah YM, Guo GL, Wang T, Krausz KW. Rifaximine is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007; 322: 391-398.
37. Kolios G, Manousou P, Bourikas G, et al. Ciprofloxacine inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 2006; 36: 720-729.
38. Ruiz ML, Villanueva SS, Luquita MG, Ikushiro S, Mottino AD, Catania VA. Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistanceassociated protein 2. Drug Metab Dispos 2007; 35: 2060-2066.
39. Ruiz ML, Villanueva SS, Luquita MG, et al. Induction of intestinal multidrug resistance-associated protein 2 (Mrp2) by spironolactone in rats. Eur J Pharmacol 2009; 623: 103-106.
40. Bendtzen K, Hansen PR, Rieneck K & The Spironolactone /Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor alpha and interferon gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151-158.
41. Miura R, Nakamura K, Miura D, et al. Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. J Pharmacol Sci 2006; 101: 256-259.
42. Johnson LA, Govani SM, Joyce JC, et al. Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm Bowel Dis 2012; 18: 1315-1324.
43. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006; 130: 341-348.